Illumina Inc. (ILMN) News
Filter ILMN News Items
ILMN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ILMN News Highlights
- ILMN's 30 day story count now stands at 21.
- Over the past 10 days, the trend for ILMN's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
- The most mentioned tickers in articles about ILMN are GENE, EU and GAME.
Latest ILMN News From Around the Web
Below are the latest news stories about ILLUMINA INC that investors may wish to consider to help them evaluate ILMN as an investment opportunity.
Here's Why You Should Retain Illumina (ILMN) Stock for NowInvestors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position. |
Small Caps Are On A Tear Including Speculative BiotechsSo far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. |
Nucleus Genomics Wants To Make Personalized Health Care a RealityNORTHAMPTON, MA / ACCESSWIRE / December 21, 2023 / Illumina A New York-based startup is on a mission to bring the power of whole-genome sequencing to the world Originally published on Illumina News Center Nucleus Genomics is realizing the dream set ... |
Heard on the Street: Illumina Nears the End of Its Painful Grail SagaGrail’s screening test, called Galleri, could one day help save countless lives by catching cancer in the bloodstream early. After losing in court [against the Federal Trade Commission](https://www.wsj.com/health/healthcare/court-sides-with-ftc-finding-illumina-grail-deal-anticompetitive-ad2efe8d), the company has finally [thrown in the towel](https://www.wsj.com/health/healthcare/illumina-to-divest-itself-of-cancer-test-maker-grail-3f74f1e8) on keeping Grail. The maker of gene-sequencing machines said Sunday it will pursue the divestiture of Grail through a third-party sale or capital markets transaction, with a goal of completing terms by the middle of 2024. |
S&P 500 Gains and Losses Today: Enphase's Cost Cutting Charges Up Solar StocksThe S&P 500 gained 0.6% on Tuesday, Dec. 19, 2023, amid optimism on Fed rate cuts, strong housing data, and the traditional "Santa Claus rally." |
Illumina To Webcast Upcoming Investor ConferenceIllumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: |
FTC, DOJ finalize merger guidelines that could impede healthcare M&AThe new guidelines should give regulators sharper teeth in going after vertical and cross-market deals that have historically been difficult to challenge. |
Carl Icahn to initiate proxy battle with Illumina — againActivist investor Carl Icahn is gearing up to initiate another proxy fight at gene sequencing giant Illumina (ILMN) , aiming to appoint additional nominees to the company's board. This comes just months after shareholders elected one of his candidates amid criticisms of Illumina's acquisition of Grail. Now, Icahn is looking to elect more of his representatives in the boardroom as Illumina faces challenges following the Grail deal. Yahoo Finance's Ines Ferré breaks down all the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. |
A Lesser-Known Application of Genomics: Reducing Cow Burp IntensityDataGene's Sustainability Index for dairy cattle herds combats this significant driver of global warming NORTHAMPTON, MA / ACCESSWIRE / December 19, 2023 / Illumina Originally published on Illumina News Center Methane is 28 times more powerful a greenhouse ... |
The 2023 stock market rally isn't just about 7 stocks anymoreThe market rally over the last month hasn't been driven by the "Magnificent Seven" tech stocks, a promising sign that it has legs. |